Unigene Laboratories Inc said on Thursday it has begun Phase III clinical trials for FORTICAL Injection in the U.S. and U.K.
The trials are being conducted under an application allowed by the U.S. Food and Drug Administration and the U.K. Clinical Trials Exemption Scheme, a fast track route for permission to conduct clinical trials.